Genmab reported 787M in Operating Profit for its second fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Operating Profit Change
Agios Pharmaceuticals AGIO:US $ -89.22M 2M
Alexion Pharmaceuticals ALXN:US $ 636.2M 14.1M
Amarin AMRN:US $ 8.77M 10.1M
Amgen AMGN:US $ 828M 1301M
AstraZeneca AZN:LN 1.13B 768M
Bayer BAYN:GR -2281000000 5.36B
Biomarin Pharmaceutical BMRN:US $ 11.67M 13.41M
Bluebird Bio BLUE:US $ -240.84M 9.63M
Exelixis EXEL:US $ 123.01M 127.62M
Fresenius Medical Care FME:GR € 424M 50M
Galapagos GLPG:NA -46750000 4.05M
Genmab GEN:DC 787M 255M
GlaxoSmithKline GSK:LN 1.68B 18M
GN Store Nord GN:DC 584M 128M
GRIFOLS GRF:SM € 250.6M 37.64M
H. Lundbeck A/S LUN:DC 596M 286M
Hikma Pharmaceutical HIK:LN 343M 34M
Immunogen IMGN:US $ -27.37M 1.55M
Insmed INSM:US $ -106255000 22.42M
Lonza Group LONN:SW 317M 34M
Merck MRK:GR € 1049M 6M
Novartis NOVN:VX 3.48B 1.06B
Regeneron Pharmaceuticals REGN:US $ 3347.2M 2234.5M
Seattle Genetics SGEN:US $ -89.6M 32.82M
William Demant Holding WDH:DC 1.64B 222M